Chang David F, Braga-Mele Rosa, Henderson Bonnie An, Mamalis Nick, Vasavada Abhay
From the University of California (Chang), San Francisco, California, Moran Eye Centre (Mamalis), University of Utah, Salt Lake City, Utah, and Department of Ophthalmology (Henderson), Tufts University School of Medicine, Boston, Massachusetts, USA; University of Toronto (Braga-Mele), Toronto, Ontario, Canada; Raghudeep Eye Clinic (Vasavada), Ahmedabad, India.
From the University of California (Chang), San Francisco, California, Moran Eye Centre (Mamalis), University of Utah, Salt Lake City, Utah, and Department of Ophthalmology (Henderson), Tufts University School of Medicine, Boston, Massachusetts, USA; University of Toronto (Braga-Mele), Toronto, Ontario, Canada; Raghudeep Eye Clinic (Vasavada), Ahmedabad, India.
J Cataract Refract Surg. 2015 Jun;41(6):1300-5. doi: 10.1016/j.jcrs.2015.01.014.
A 2014 online survey of the American Society of Cataract and Refractive Surgery members indicated increasing use of intracameral antibiotic injection prophylaxis compared with a comparable survey from 2007. Forty-seven percent of respondents already used or planned to adopt this measure. One half of all surgeons not using intracameral prophylaxis expressed concern about the risks of noncommercially prepared antibiotic preparations. Overall, the large majority (75%) said they believe it is important to have a commercially available antibiotic approved for intracameral injection. Assuming reasonable cost, the survey indicates that commercial availability of Aprokam (cefuroxime) would increase the overall percentage of surgeons using intracameral antibiotic injection prophylaxis to nearly 84%. Although the majority used topical perioperative antibiotic prophylaxis, and gatifloxacin and moxifloxacin were still the most popular agents, there was a trend toward declining use of fourth-generation fluoroquinolones (60%, down from 81% in 2007) and greater use of topical ofloxacin and ciprofloxacin (21%, up from 9% in 2007).
美国白内障与屈光手术学会2014年的一项在线会员调查显示,与2007年的类似调查相比,前房内注射抗生素预防法的使用有所增加。47%的受访者已经采用或计划采用这一措施。所有未采用前房内预防措施的外科医生中有一半对非商业制备的抗生素制剂的风险表示担忧。总体而言,绝大多数(75%)表示他们认为有获批用于前房内注射的市售抗生素很重要。假设成本合理,该调查表明,Aprokam(头孢呋辛)的商业供应将使使用前房内注射抗生素预防法的外科医生总体比例增至近84%。尽管大多数人采用围手术期局部抗生素预防法,加替沙星和莫西沙星仍是最常用的药物,但使用第四代氟喹诺酮类药物的趋势有所下降(从2007年的81%降至60%),局部使用氧氟沙星和环丙沙星的比例有所增加(从2007年的9%增至21%)。